文章摘要

非小细胞肺癌接受埃克替尼治疗进展后继发性T790M突变

作者: 1李剑英, 2许春伟, 2黄韵坚, 3黄章洲, 3庄武, 4陈华飞, 5魏建国
1 南通市肿瘤医院肿瘤科，江苏 南通 226361
2 福建医科大学附属福建省肿瘤医院病理科，福州 350014
3 福建医科大学附属肿瘤医院胸部肿瘤内科，福州 350014
4 浙江省荣军医院胸部疾病诊疗中心，浙江 嘉兴 314000
5 绍兴市人民医院病理科，浙江 绍兴 312000
通讯: 许春伟 Email: xuchunweibbbb@163.com
DOI: 10.3978/j.issn.2095-6959.2017.10.003

摘要

目的：探讨非小细胞肺癌(non-small cell lung cancer，NSCLC)患者接受埃克替尼治疗进展后的继发性T790M突变情况。方法：应用突变扩增阻滞系统(amplification refractory mutation system，ARMS)方法检测209例EGFR 19del或L858R突变NSCLC患者接受埃克替尼治疗进展后T790M突变状态，并分析临床特征。结果：209例NSCLC样本中，19del有123例，L858R有86例，接受埃克替尼治疗耐药后检测T790M突变型患者占45.93% (96/209)，耐药后T790M突变与19del/L858R之间差异有统计学意义(P<0.034)。结论：EGFR常见突变的NSCLC患者，19del患者接收埃克替尼治疗后更易出现T790M突变，应予以重视。
关键词： 非小细胞肺癌 19del L858R T790M

Acquired T790M mutation in patients with non-small cell lung cancer who received icotinib progress

Authors: 1LI Jianying, 2XU Chunwei, 2HUANG Yunjian, 2HUANG Zhangzhou, 3ZHUANG Wu, 4CHEN Huafei, 5WEI Jianguo
1 Department of Oncology, Nantong Tumor Hospital, Nantong Jiangsu 226361
2 Department of Pathology, Fujian Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014
3 Department of Medical Thoracic Oncology, Fujian Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014
4 Center for Chest Disease Diagnosis and Treatment, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000
5 Department of Pathology, Shaoxing People’s Hospital, Shaoxing Zhejiang 312000, China

CorrespondingAuthor: XU Chunwei Email: xuchunweibbbb@163.com

DOI: 10.3978/j.issn.2095-6959.2017.10.003

Abstract

Objective: To investigate the acquired T790M situation of the non-small cell lung cancer patients who received icotinib treatment progress. Methods: The ARMS method was used to detect the samples in 209 cases of EGFR 19del or L858R mutation non-small cell lung cancer. Results: There were 123 cases accompanied 19del and 86 cases accompanied L858R in 209 cases non-small cell lung cancer samples who received icotinib treatment progress, the acquired T790M mutation type patients was 45.93% (96/209), icotinib treatment resistance after the acquired T790M mutation with 19 del/L858R group had statistical difference (P<0.034). Conclusion: 19 del patients who received treatment for icotinib are more likely to appear acquired T790M mutation than L858R patients from NSCLC, and we should attach importance to it.
Keywords： non-small cell lung cancer 19del L858R T790M

文章选项

下载引文

分享